Clinical and Economic Outcomes
HDx therapy enabled by the Theranova dialyzer can help free resources and relieve the strain on healthcare systems.1,2
Importance of Economics
As part of evidence-based policy decisions, economic evaluations are invaluable tools for enabling national healthcare systems to assess present and future demands for resource use and healthcare service delivery3
Primary clinical studies illuminate the benefits of HDx therapy enabled by Theranova dialyzer
Lee et al. Cardiovascular Risk Comparison between Expanded Hemodialysis Using Theranova and Online Hemodiafiltration (CARTOON): A Multicenter Randomized Controlled Trial.
HDx therapy with Theranova membrane was similar to online- HDF in most cardiovascular parameters, blood markers, patient-reported outcomes and in both all-cause mortality and cardiovascular mortality.4
Ariza JG et al. An initial evaluation of expanded hemodialysis on hospitalizations, drug utilization, costs, and patient utility in Colombia.
HDx therapy was associated with statistically significant and clinically meaningful fewer hospitalization days and lower medication doses compared to high flux HD in a 2 year real world study.5
Blackowicz MJ et al. Economic evaluation of expanded hemodialysis with the Theranova 400 dialyzer: A post hoc evaluation of a randomized clinical trial in the United States.
In this post-hoc analysis of a randomized clinical trial, the HDx therapy with Theranova dialyzer was associated with lower healthcare costs than standard high-flux HD. Theranova dialyzer is associated with a reduced hospitalization rate per patient year and is expected to be a cost-saving therapy, based on this significant reduction in hospitalization events.2
Hadad-Arrascue F et al. Expanded hemodialysis as effective alternative to on-line hemodiafiltration: A randomized mid-term clinical trial.
This randomized, controlled study comparing HDx therapy with online HDF over 24 weeks found that HDx therapy may be an attractive option for long-term dialysis, particularly since it is easy to implement and not dependent on on-line HDF equipment.6
Lim JH et al. Medium Cut-Off Dialyzer Improves Erythropoiesis Stimulating Agent Resistance in a Hepcidin-Independent Manner in Maintenance Hemodialysis Patients: Results from a Randomized Controlled Trial.
MCO dialyzer membrane improves ESA resistance over time compared to high-flux HD in maintenance HD patients. MCO dialyzer membrane provides superior removal of large middle molecules, reducing inflammatory cytokines potentially improving iron metabolism.7
Kandi M et al. Clinical Outcomes with Medium Cut-Off Versus High-Flux Hemodialysis Membranes: A Systematic Review and Meta-Analysis.
Evidence generated to date supports that the MCO membrane increases the clearance of a wide range of large middle molecules and likely reduces inflammatory mediators, with a minimal transient reduction in serum albumin concentration.8
Cozzolino M et al. Effects of a medium cut-off Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study.
HDx therapy showed a statistically significant decrease in the rate of infections. Additionally, this study validated MCO membranes’ ability to reduce serum concentration of soluble inflammatory mediators, including cytokines.9
Sanabria RM, Hutchison CA, Vesga JI, et al. Expanded hemodialysis and its effects on hospitalizations and medication usage: a cohort study.
A switch to HDx therapy enabled by Theranova dialyzer was associated with significant reduction in hospital days, IV ESA/iron doses, and improvement in erythropoietin resistance, which can inform treatment modality decisions and reduce the impact of ESKD on patients and healthcare systems.1
Reference Library
Hear from patients, nephrologists, and nurses alike share their experience prescribing HDx therapy. Be reassured by the pioneering commitment of Baxter to dialysis patients the world over and learn how Theranova dialyzers are made.
HDx Therapy Evidence Compendium
On-going research and clinical reporting are an integral part of the HDx therapy journey. Explore the the expanding evidence related to HDx therapy enabled by Theranova dialyzer that nephrologists around the world continue to generate.
HDx Therapy Brochure
Here you can find the HDx therapy brochure with more information about prescribing HDx therapy for your hemodialysis patients.
HDx Therapy Specification Sheets
Here you can find the detailed profiles of Theranova dialyzers.
Important Safety Information
Theranova dialyzers are indicated for treatment of chronic and acute renal failure by hemodialysis.
*Do not use Theranova dialyzers in HDF or HF mode.
For safe and proper use of this device, please refer to Instructions for Use.
